A phase II trial of chlorambucil in non-small cell lung cancer.
A Phase II trial of high-dose chlorambucil at 108 mg/m2 was undertaken in non-small cell lung cancer. No complete or partial objective responses were observed, and significant toxicity, including nausea, vomiting, and seizures, was noted. Chlorambucil at this dose and schedule of administration is not recommended for the treatment of non-small cell lung cancer.
Gentile
P S
PS
Division of Medical Oncology, University of Louisville School of Medicine, KY 40292.
Woodcock
T M
TM
Blumenreich
M S
MS
Epremian
B E
BE
Seeger
J
J
Sheth
S P
SP
Hamm
J T
JT
Sherrill
E J
EJ
Allegra
J C
JC
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002699:Chlorambucil / Q000009:adverse effects*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D002699:Chlorambucil